戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 sence of 3-isobutyl-1-methylxanthine, a cAMP phosphodiesterase inhibitor.
2 pretreatment with rolipram, a selective cAMP phosphodiesterase inhibitor.
3 ioned media factor, phosphodiesterase or the phosphodiesterase inhibitor.
4 36Cl- efflux in response to beta-agonist and phosphodiesterase inhibitor.
5 of treatment with milrinone, a type III cAMP phosphodiesterase inhibitor.
6 CnAbeta(-/-) mice, however, are sensitive to phosphodiesterase inhibitor.
7 ited by a cAMP antagonist and increased by a phosphodiesterase inhibitor.
8 s rolipram, a cyclic adenosine monophosphate phosphodiesterase inhibitor.
9 " theophylline, the archetypal non-selective phosphodiesterase inhibitor.
10 racellular cAMP, by cAMP derivatives, and by phosphodiesterase inhibitors.
11 nd 28, analogues of recently described novel phosphodiesterase inhibitors.
12  membrane was prevented by pretreatment with phosphodiesterase inhibitors.
13 ed by intraperitoneal injection of selective phosphodiesterase inhibitors.
14 mammalian cell line (CHO cells) and used the phosphodiesterase inhibitor 3-isobutyl-1-methyl-xanthine
15 denylate cyclase activator forskolin and the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine
16 n, the cone outer segment was exposed to the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine
17  (dbcGMP, 300 microM) in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine
18 nto immature mouse oocytes maintained in the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine
19 yclase, into the preBotC with or without the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine
20 was inhibited by >80% in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine
21  (5x10(-4) mol/L) and was potentiated by the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine
22  the cAMP agonist, 8-bromo-cAMP, or with the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine,
23 e agents was enhanced in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine.
24 ovine carotid artery smooth muscles with the phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine
25 itroso-N-acetylpenicillamine (SNAP), and the phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine
26     A pilot experiment demonstrated that the phosphodiesterase inhibitor, 3-isobutylmethylxanthine (I
27               The response of T cells to the phosphodiesterase inhibitor, 4-(3'-cyclopentyloxy-4'-met
28 do)adenosine, dibutyryl cAMP, forskolin, and phosphodiesterase inhibitors all promoted deturgescence
29 vely coupled to adenylyl cyclase, and a cAMP phosphodiesterase inhibitor ameliorated the physiologica
30                   Papaverine is a well-known phosphodiesterase inhibitor and also modifies the mitoge
31                    Zaprinast is a well known phosphodiesterase inhibitor and lead compound for silden
32  to use in vitro assays to identify a potent phosphodiesterase inhibitor and then to investigate its
33 Ibudilast is a multi-target drug, as it is a phosphodiesterase inhibitor and toll-like receptor 4 (TL
34 more traditionally used vasodilators include phosphodiesterase inhibitors and (for those with recurre
35 d in T84 cells with application of class III phosphodiesterase inhibitors and in wild-type murine int
36  growing interest in novel therapies such as phosphodiesterase inhibitors and neuropeptides.
37 ion should be treated with therapies such as phosphodiesterase inhibitors and prostacyclin analogues.
38                                     The cGMP-phosphodiesterase inhibitors and YC-1 increased the prod
39 ed with the combination of oral enoximone (a phosphodiesterase inhibitor) and oral metoprolol at two
40 IgE therapy, adenosine receptor antagonists, phosphodiesterase inhibitors) and potential (chemokine r
41 rotein, cyclic nucleotide phosphodiesterase, phosphodiesterase inhibitor, and aggregation-stage adeny
42 with 8 Br-cAMP or isomethylbutyl xanthine, a phosphodiesterase inhibitor, and by stimulation of Ca2+
43 icked by an adenylyl cyclase activator and a phosphodiesterase inhibitor, and these responses can be
44 s confirmed by adenylate cyclase activators, phosphodiesterase inhibitors, and most notably by stimul
45  apnea, deep vein thrombosis, stroke, use of phosphodiesterase inhibitors, and smoking status.
46 drenergic receptor agonists and antagonists, phosphodiesterase inhibitors, angiotensin-converting enz
47                     Pretreatment with a cGMP phosphodiesterase inhibitor antagonized the anxiogenic e
48                Positive inotropes, including phosphodiesterase inhibitors, are associated with increa
49 to 51.5% over 24 h and, in the presence of a phosphodiesterase inhibitor, blunted isoproterenol-stimu
50 creased cAMP levels within 3 minutes without phosphodiesterase inhibitors by measuring real-time cAMP
51                Increasing cellular cGMP with phosphodiesterase inhibitors, by stimulation of soluble
52 rapies, namely: (a) toll-like receptors, (b) phosphodiesterase inhibitors, (c) peroxisome proliferato
53 opes of interest included adrenergic agents, phosphodiesterase inhibitors, calcium sensitizers, myosi
54 or environmental acidification, while a cGMP-phosphodiesterase inhibitor circumvents egress repressio
55                       We selected the Type 4 phosphodiesterase inhibitor, CP80,633, based on its inhi
56 f cAMP, or a blockade of cAMP degradation by phosphodiesterase inhibitor decreased NLRP3 activation.
57 es induced by methylisobutylxanthine (a cAMP phosphodiesterase inhibitor), dexamethasone, and insulin
58        Targeting these pathways by using the phosphodiesterase inhibitor dipyridamole restored immune
59 ossover trials with beta blocker drugs and a phosphodiesterase inhibitor during steady-state and grad
60 e attenuation of platelet aggregation by the phosphodiesterase inhibitor EHNA (a non-ABCC4 substrate)
61 s include drugs such as nitric oxide donors, phosphodiesterase inhibitors, endothelin antagonists, an
62 DGF and 3-isobutyl-1-methylxanthine (IBMX, a phosphodiesterase inhibitor) enhanced the accumulation o
63  The antidepressant drug rolipram, a type IV phosphodiesterase inhibitor, enhances IL-10 production b
64                          At higher doses the phosphodiesterase inhibitor, enoximone, has been shown t
65 ation of dibutyryl cyclic AMP (5 mM) and the phosphodiesterase inhibitor IBMX (0.5 mM) prevented the
66                           Application of the phosphodiesterase inhibitor IBMX increased fluorescence
67                                    Thus, the phosphodiesterase inhibitor IBMX promotes the actions of
68 all regions of striatum, we administered the phosphodiesterase inhibitor IBMX to animals treated with
69 -) current following a brief exposure to the phosphodiesterase inhibitor IBMX to monitor indirectly t
70 ydroxylabd-14-en-11-one (forskolin), the pan-phosphodiesterase inhibitor IBMX, and EPAC inhibitors 5,
71 -hydrolysable cAMP analogue 8-Br-cAMP or the phosphodiesterase inhibitor IBMX, suggesting high phosph
72 y the L-type channel blocker nifedipine, the phosphodiesterase inhibitor IBMX, the adenylyl cyclase a
73 s of PKA, a permeable analog of cAMP and the phosphodiesterase inhibitor IBMX, we show that PKA activ
74 d circadian rhythms are mimicked by a potent phosphodiesterase inhibitor, IBMX (3-isobutyl-1-methylxa
75 ffect of SNAP on mIPSCs in the presence of a phosphodiesterase inhibitor, IBMX.
76                               Agents such as phosphodiesterase inhibitors, immunophilin ligands, and
77 gues, endothelin-1-receptor antagonists, and phosphodiesterase inhibitors, improve clinical function
78      Given our interest in cyclic nucleotide phosphodiesterase inhibitors in chronic lymphocytic leuk
79 rgic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors in heart failure have demon
80 gated the role of pulmonary vasodilators and phosphodiesterase inhibitors in selected patients receiv
81 ata indicate that the clinical evaluation of phosphodiesterase inhibitors in the treatment of patient
82 line by beta-adrenoreceptor agonists and cGI-phosphodiesterase inhibitors in transformed nasal polyp
83     Conversely, intracellular injection of a phosphodiesterase inhibitor increased MSN neuron membran
84  another cAMP analogue (8-bromo-cAMP) or the phosphodiesterase inhibitor indolidan.
85                                         When phosphodiesterase inhibitor is increased with time, mimi
86                    Ibudilast, a nonselective phosphodiesterase inhibitor, is used clinically in Asia
87                 Addition of the nonselective phosphodiesterase inhibitor, isobutyl methylxanthine (IB
88 nylate cyclase activator, forskolin, and the phosphodiesterase inhibitor isobutylmethyl xanthine (IBM
89 st differentiation and to synergize with the phosphodiesterase inhibitor isobutylmethylxanthine (IBMX
90 e transient, but in the presence of the cAMP phosphodiesterase inhibitor isobutylmethylxanthine (IBMX
91             Increasing cAMP levels using the phosphodiesterase inhibitor isobutylmethylxanthine (IBMX
92  cGMP-gated channel agonist 8-bromo-cGMP, or phosphodiesterase inhibitor isobutylmethylxanthine to mi
93                                   Forskolin, phosphodiesterase inhibitor isobutylmethylxanthine, and
94 glucose concentration in the presence of the phosphodiesterase inhibitor isobutylmethylxanthine.
95 rown adipogenesis in vitro in the absence of phosphodiesterase inhibitor isobutylmethylxanthine.
96 f renal cortical slices in the presence of a phosphodiesterase inhibitor isobutylmethylxantine did no
97            Incubation of IMCD cells with the phosphodiesterase inhibitors isomethylbutylxanthine or Z
98 at administration of pentoxifylline (PTX), a phosphodiesterase inhibitor known to inhibit Th1 cytokin
99 nt sensitivities to the calmodulin-dependent phosphodiesterase inhibitors, KS505a and SCH51866.
100                         Sildenafil, a type 5 phosphodiesterase inhibitor, lowers pulmonary vascular r
101                                     The cGMP phosphodiesterase inhibitor M&B 22948 (30 microM) and 8-
102  in an excitable system and suggest that the phosphodiesterase inhibitor may be under selection becau
103 hat CGRP gene transfer alone and with a cAMP phosphodiesterase inhibitor may be useful for the treatm
104 rovide new insights into mechanisms by which phosphodiesterase inhibitors may block malaria parasite
105  eNOS, alone or in combination with a type V phosphodiesterase inhibitor, may constitute a new therap
106 ocorticoid dexamethasone (dex), insulin, the phosphodiesterase inhibitor methylisobutylxanthine (IBMX
107  in endogenous levels of cAMP induced by the phosphodiesterase inhibitor milrinone mirrored the actio
108                                              Phosphodiesterase inhibitors modulate several pathways c
109                           Key points include phosphodiesterase inhibitors most likely confer benefit,
110                      The effect of a topical phosphodiesterase inhibitor on atopic dermatitis lesiona
111  We examined the effect of BBB022, a type IV phosphodiesterase inhibitor, on blood-brain barrier (BBB
112 tion with sildenafil, a specific type 5 cGMP phosphodiesterase inhibitor, on flow-mediated dilation i
113 lyze the effect of rolipram, a cAMP-specific phosphodiesterase inhibitor, on TNF-alpha production in
114 d-type murine intestines with class I or III phosphodiesterase inhibitors or with activators of type
115 tion inducers methylisobutylxanthine (a cAMP phosphodiesterase inhibitor) or Forskolin, both of which
116                           Treatment with the phosphodiesterase inhibitor papaverine led to a mass shi
117                                              Phosphodiesterase inhibitors (PDE-Is) have been shown to
118                                              Phosphodiesterase inhibitors (PDEIs), used frequently in
119                                       Type 5 phosphodiesterase inhibitors potentiate the ability of N
120 utyl-1-methylxanthine (IBMX), a non-specific phosphodiesterase inhibitor, potentiated the effect of S
121 enous addition of IL-12, while Ro 20-1724, a phosphodiesterase inhibitor, potentiated the effects of
122 s induce the current suppressed by AMPA, and phosphodiesterase inhibitors prevent the suppression.
123 osuppressant, rapamycin, and theophylline, a phosphodiesterase inhibitor, promote marked dephosphoryl
124                       Treatment of mice with phosphodiesterase inhibitors rescued the sleep-deprivati
125 pathway by rolipram, a selective Type 4 cAMP phosphodiesterase inhibitor, reverses MK-801-induced imp
126                   Subsequent addition of the phosphodiesterase inhibitor Ro 20-1724 (0.5 mM) increase
127  inhibitor MDL 12230A (20 microM), or by the phosphodiesterase inhibitor Ro 20-1724 (50 microM).
128                                          The phosphodiesterase inhibitor Ro 20-1724 dose-dependently
129 nic (12-15 day) exposure to the type IV cAMP phosphodiesterase inhibitor, Ro20-1724, were examined.
130 hat pharmacologic elevation of cAMP with the phosphodiesterase inhibitor Rolipram suppresses tumor ce
131 o-cAMP and potentiated by the cAMP-dependent phosphodiesterase inhibitor rolipram, suggesting that it
132                 Pretreatment with the type 4 phosphodiesterase inhibitor, rolipram, abolished thapsig
133 , alone and synergistically with the type IV phosphodiesterase inhibitor, rolipram, increased neutrop
134                       Infusion of the type 4 phosphodiesterase inhibitor, rolipram, prevented thapsig
135         Concentrations of a type IV-specific phosphodiesterase inhibitor, rolipram, which had no sign
136 t phenotypes, an effect mimicked by the cAMP phosphodiesterase inhibitor, rolipram.
137 diopathic PAH population, treatment with the phosphodiesterase inhibitor sildenafil was associated wi
138 ice and decreased upon administration of the phosphodiesterase inhibitor sildenafil, which augments e
139 at is enhanced by pretreatment with the cGMP phosphodiesterase inhibitor sildenafil.
140 ies evaluating anti-endothelin-1 (bosentan), phosphodiesterases inhibitors (sildenafil), and prostano
141 ayed gastric emptying can be reversed with a phosphodiesterase inhibitor, sildenafil.
142               Loss of label is suppressed by phosphodiesterase inhibitors such as ADP-ribose and p-ni
143                                              Phosphodiesterase inhibitors such as amrinone may be fou
144                             Potent, specific phosphodiesterase inhibitors such as E4021 may prove to
145 cell permeable cGMP derivatives, or the cGMP phosphodiesterase inhibitor sulindac sulfone (exisulind,
146 , 5alpha-reductase inhibitors (finasteride), phosphodiesterase inhibitors (tadalafil), anticholinergi
147         Milrinone is an intravenously active phosphodiesterase inhibitor that acts rapidly and exerts
148 horylated in the presence of theophylline, a phosphodiesterase inhibitor that creates high cAMP level
149  dichotomy was recapitulated by zaprinast, a phosphodiesterase inhibitor that elevated cGMP and separ
150  and the decrease is reversed by rolipram, a phosphodiesterase inhibitor that raises cAMP and leads t
151                          Cilostazol is a new phosphodiesterase inhibitor that suppresses platelet agg
152 y 36,000 compounds, we identified a class of phosphodiesterase inhibitors that suppress let-7 targets
153                        In contrast, the cAMP phosphodiesterase inhibitor, theophylline, inhibited mTO
154 e inotropic response of myocardial tissue to phosphodiesterase inhibitors through a mechanism indepen
155                      The addition of cGMP or phosphodiesterase inhibitors to cultures of mature gamet
156 trated the ability of selective high-potency phosphodiesterase inhibitors to reduce prostaglandin E2,
157 -[1,2,4]oxadiazolo[4,3-a]quinoxalin, and the phosphodiesterase inhibitor Viagra, which modulate NO-de
158 y Nef is inhibited by the calcium/calmodulin phosphodiesterase inhibitor W-7 but not by the protein k
159  of a membrane-permeant analog of cAMP and a phosphodiesterase inhibitor was not sufficient to induce
160  regulator of external cAMP levels, the cAMP phosphodiesterase inhibitor, we can explain the natural
161 d and decreases in PAP in response to a cAMP phosphodiesterase inhibitor were enhanced by AdRSVCGRP.
162 lo[3,4-c]pyridine series of human eosinophil phosphodiesterase inhibitors were improved by tying the
163  as well as more potent cyclic GMP-dependent phosphodiesterase inhibitors were shown to cause inhibit
164 tor agonists, dibutyryl cAMP, forskolin, and phosphodiesterase inhibitors were used to modulate physi
165 tivation of adenylate cyclase, as well as by phosphodiesterase inhibitors, when cAMP-dependent regula
166 a 30 min treatment of slices with the type V phosphodiesterase inhibitor zaprinast (20 microm) plus t
167 roduced and potentiated by the cGMP-specific phosphodiesterase inhibitor zaprinast but not the inacti
168                                     The cGMP phosphodiesterase inhibitor zaprinast enhanced the vasod
169 he guanylate cyclase activator YC-1, and the phosphodiesterase inhibitor zaprinast greatly reduced sp
170                            The specific cGMP phosphodiesterase inhibitor zaprinast reduced the freque
171  to bradykinin and the type V cGMP-selective phosphodiesterase inhibitor zaprinast were enhanced, whe
172 ave used this natural mutation, and the cGMP phosphodiesterase inhibitor zaprinast, in wild-type and
173 gondii In doing so, we took advantage of the phosphodiesterase inhibitor zaprinast, which we show act
174 sion of bradykinin and a cyclic GMP-specific phosphodiesterase inhibitor, zaprinast (20 mg/kg), resul
175 lase, and was potentiated by a cGMP-specific phosphodiesterase inhibitor, zaprinast.

 
Page Top